EULAR points to consider for conducting clinical trials and observational studies in individuals at risk of rheumatoid arthritis von Mankia, K, Siddle, HJ, Kerschbaumer, A, Alpizar Rodriguez, D, Catrina, AI, Cañete, JD, Cope, AP, Daien, CI, Deane, KD, El Gabalawy, H, Finckh, A, Holers, VM, Koloumas, M, Ometto, F, Raza, K, Zabalan, C, van der Helm-van Mil, A, van Schaardenburg, D, Aletaha, D, Emery, P

Volltext bestellen

EULAR points to consider for conducting clinical trials and observational studies in individuals at risk of rheumatoid arthritis von Mankia, K., Siddle, H.J., Kerschbaumer, A., Rodriguez, D.A., Catrina, A.I., Canete, J.D., Cope, A.P., Daien, C.I., Deane, K.D., Gabalawy, H. el, Finckh, A., Holers, V.M., Koloumas, M., Ometto, F., Raza, K., Zabalan, C., Helm-van Mil, A. van der, Schaardenburg, D. van, Aletaha, D., Emery, P.

Volltext bestellen

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update von Smolen, JS, Landewe, RBM, Bijlsma, JWJ, Burmester, GR, Dougados, M, Kerschbaumer, A, McInnes, IB, Sepriano, A, van, Vollenhoven RF, de, Wit M

Volltext